Search Page

1

Cite

Share

Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.

Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, Roy S. Chakraborty A, et al. Among authors: rordorf c. Clin Pharmacokinet. 2012 Jun 1;51(6):e1-18. doi: 10.2165/11599820-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22550964 Free PMC article. Review.

Cite

Share

2

Cite

Share

Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.

Rordorf CM, Choi L, Marshall P, Mangold JB. Rordorf CM, et al. Clin Pharmacokinet. 2005;44(12):1247-66. doi: 10.2165/00003088-200544120-00004. Clin Pharmacokinet. 2005. PMID: 16372823 Review.

Cite

Share

3

Cite

Share

Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration.

Kovarik JM, Bartlett M, Rordorf C, Antunes MC, Winter S, Marbach P, van Marle S. Kovarik JM, et al. Among authors: rordorf c. Int J Clin Pharmacol Ther. 2010 Feb;48(2):103-8. doi: 10.5414/cpp48103. Int J Clin Pharmacol Ther. 2010. PMID: 20137762 Clinical Trial.

Cite

Share

4

Cite

Share

Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib.

Scott G, Vinluan Reynolds C, Milosavljev S, Langholff W, Shenouda M, Rordorf C. Scott G, et al. Among authors: rordorf c. Clin Pharmacokinet. 2004;43(5):341-8. doi: 10.2165/00003088-200443050-00006. Clin Pharmacokinet. 2004. PMID: 15080766 Clinical Trial.

Cite

Share

5

Cite

Share

Pharmacokinetics of lumiracoxib in plasma and synovial fluid.

Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavljev S, Weaver M, Huff JP, Ruff DA. Scott G, et al. Among authors: rordorf c. Clin Pharmacokinet. 2004;43(7):467-78. doi: 10.2165/00003088-200443070-00003. Clin Pharmacokinet. 2004. PMID: 15139795 Clinical Trial.

Cite

Share

6

Cite

Share

The PKC inhibitor AEB071 may be a therapeutic option for psoriasis.

Skvara H, Dawid M, Kleyn E, Wolff B, Meingassner JG, Knight H, Dumortier T, Kopp T, Fallahi N, Stary G, Burkhart C, Grenet O, Wagner J, Hijazi Y, Morris RE, McGeown C, Rordorf C, Griffiths CE, Stingl G, Jung T. Skvara H, et al. Among authors: rordorf c. J Clin Invest. 2008 Sep;118(9):3151-9. doi: 10.1172/JCI35636. J Clin Invest. 2008. PMID: 18688284 Free PMC article. Clinical Trial.

Cite

Share

7

Cite

Share

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes.

Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, Wittkowski H, Bek S, Hartmann N, Bosset S, Hawkins PN, Jung T. Lachmann HJ, et al. Among authors: rordorf c. J Exp Med. 2009 May 11;206(5):1029-36. doi: 10.1084/jem.20082481. Epub 2009 Apr 13. J Exp Med. 2009. PMID: 19364880 Free PMC article.

Cite

Share

8

Cite

Share

Effect of rifampin on apparent clearance of everolimus.

Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C. Kovarik JM, et al. Among authors: rordorf c. Ann Pharmacother. 2002 Jun;36(6):981-5. doi: 10.1345/aph.1A384. Ann Pharmacother. 2002. PMID: 12022896 Clinical Trial.

Cite

Share

9

Cite

Share

Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects.

Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C. Mangold JB, et al. Among authors: rordorf c. Drug Metab Dispos. 2004 May;32(5):566-71. doi: 10.1124/dmd.32.5.566. Drug Metab Dispos. 2004. PMID: 15100180

Cite

Share

10

Cite

Share

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).

Kuemmerle-Deschner JB, Ramos E, Blank N, Roesler J, Felix SD, Jung T, Stricker K, Chakraborty A, Tannenbaum S, Wright AM, Rordorf C. Kuemmerle-Deschner JB, et al. Among authors: rordorf c. Arthritis Res Ther. 2011 Feb 28;13(1):R34. doi: 10.1186/ar3266. Arthritis Res Ther. 2011. PMID: 21356079 Free PMC article. Clinical Trial.

Cite

Share